公开(公告)号：AU2016209056B2

公开(公告)日：2021-01-28

申请号：AU2016209056

申请日：2016-01-25

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  CHEUNG SARAH K C ,  CHUANG PO-KAI ,  HSU TSUI-LING

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

公开(公告)号：CA2937123A1

公开(公告)日：2015-07-23

申请号：CA2937123

申请日：2015-01-16

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: A61K39/395 ,  G01N33/574

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：AU2015377230A1

公开(公告)日：2017-07-13

申请号：AU2015377230

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：CA2972067A1

公开(公告)日：2016-07-21

申请号：CA2972067

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIHH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/00 ,  A61K39/42 ,  C07K16/28 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

公开(公告)号：AU2015206370A1

公开(公告)日：2016-07-07

申请号：AU2015206370

申请日：2015-01-16

Applicant: ACADEMIA SINICA

Inventor： LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  WONG CHI-HUEY

IPC: C12N5/0793

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：WO2015109180A3

公开(公告)日：2015-10-15

申请号：PCT/US2015011748

申请日：2015-01-16

Applicant: ACADEMIA SINICA ,  WONG CHI-HUEY

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  HSU TSUI-LING ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C12N5/0793

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

Abstract translation: 本文公开了包含与SSEA-4结合的抗体或其抗原结合片段的药物组合物，以及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，肺，乳腺，小鼠，食管，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。

公开(公告)号：AU2016209056A1

公开(公告)日：2017-07-20

申请号：AU2016209056

申请日：2016-01-25

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  CHEUNG SARAH K C ,  CHUANG PO-KAI ,  HSU TSUI-LING

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

公开(公告)号：AU2008353452A1

公开(公告)日：2009-10-01

申请号：AU2008353452

申请日：2008-05-29

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  CHEN SZU-TING ,  HSU TSUI-LING

IPC: G01N33/53

Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-alpha is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-alpha secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

公开(公告)号：GB2458715A

公开(公告)日：2009-09-30

申请号：GB0812915

申请日：2008-07-15

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  HSU TSUI-LING ,  CHEN SZU-TING

IPC: A61K39/395 ,  C07K16/28

Abstract: A pharmaceutical composition is disclosed comprising an effective amount of an antibody directed against at least one cellular receptor to modulate the effects of a pathogen infection, wherein the modulation comprises at least inhibition of pro-inflammatory cytokine secretion and does not affect secretion of cytokines that affect viral clearance. The cellular receptor may be the DLVR1 / CLEC5A (DVLR1, MDL-1) receptor. The pathogen may be a hepatitis virus or a flavivirus (e.g. Japanese encephalomyelitis virus or dengue virus). Use of an anti-DLVR1/CLEC5A antibody in the treatment of a flavivirus infection is claimed. A method comprising obtaining a fusion protein comprising a binding domain of a DLVR1/CLEC5A receptor and a domain that allows affixing to a substrate, contacting the fusion protein with a flavivirus to determine if the pathogen binds to the binding domain of the fusion, and detecting whether the pathogen is bound to the fusion protein, is also claimed.

公开(公告)号：ES2902032T3

公开(公告)日：2022-03-24

申请号：ES15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  HSU TSUI-LING ,  LOU YI-WEI ,  LIN CHIH-WEI ,  YEH SHIH-CHI ,  WU CHUNG-YI ,  WU HAN-CHUNG

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal humanizado aislado que se une específicamente a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1, en el que el anticuerpo comprende un VH que tiene la SEQ ID NO: 147 y un VL que tiene la SEQ ID NO: 148.